These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23825585)

  • 1. MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia.
    Fang Y; Zhong L; Lin M; Zhou X; Jing H; Ying M; Luo P; Yang B; He Q
    PLoS One; 2013; 8(6):e66915. PubMed ID: 23825585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diptoindonesin G promotes ERK-mediated nuclear translocation of p-STAT1 (Ser727) and cell differentiation in AML cells.
    Gao J; Fan M; Xiang G; Wang J; Zhang X; Guo W; Wu X; Sun Y; Gu Y; Ge H; Tan R; Qiu H; Shen Y; Xu Q
    Cell Death Dis; 2017 May; 8(5):e2765. PubMed ID: 28471454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells.
    Congleton J; MacDonald R; Yen A
    Leukemia; 2012 Jun; 26(6):1180-8. PubMed ID: 22182854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.
    Packer LM; Rana S; Hayward R; O'Hare T; Eide CA; Rebocho A; Heidorn S; Zabriskie MS; Niculescu-Duvaz I; Druker BJ; Springer C; Marais R
    Cancer Cell; 2011 Dec; 20(6):715-27. PubMed ID: 22169110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib synergizes with ATRA to trigger granulocytic differentiation in ATRA resistant acute promyelocytic leukemia cell lines via Lyn inhibition-mediated activation of RAF-1/MEK/ERK.
    Ding M; Weng XQ; Sheng Y; Wu J; Liang C; Cai X
    Food Chem Toxicol; 2018 Sep; 119():464-478. PubMed ID: 29097117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity.
    Heo SK; Noh EK; Yoon DJ; Jo JC; Park JH; Kim H
    PLoS One; 2014; 9(2):e98859. PubMed ID: 24918603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of mitogen-activated protein kinase in signal transducer and activator of transcription-1 mediated differentiation induced by bortezomib in acute myeloid leukemia cells.
    Zhou X; Fang Y; Jing H; Zhong L; Luo P; Song H; Yang B; He Q
    Mol Carcinog; 2013 Jan; 52(1):18-28. PubMed ID: 22006557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
    Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
    Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
    Nam S; Williams A; Vultur A; List A; Bhalla K; Smith D; Lee FY; Jove R
    Mol Cancer Ther; 2007 Apr; 6(4):1400-5. PubMed ID: 17431118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HER2 inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by activating MEK/ERK mediated RARα/STAT1 axis.
    Shao X; Liu Y; Li Y; Xian M; Zhou Q; Yang B; Ying M; He Q
    Sci Rep; 2016 Apr; 6():24589. PubMed ID: 27074819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
    Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
    Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia.
    Cooper MJ; Cox NJ; Zimmerman EI; Dewar BJ; Duncan JS; Whittle MC; Nguyen TA; Jones LS; Ghose Roy S; Smalley DM; Kuan PF; Richards KL; Christopherson RI; Jin J; Frye SV; Johnson GL; Baldwin AS; Graves LM
    PLoS One; 2013; 8(6):e66755. PubMed ID: 23826126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
    Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
    Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib.
    Dumka D; Puri P; Carayol N; Lumby C; Balachandran H; Schuster K; Verma AK; Terada LS; Platanias LC; Parmar S
    Leuk Lymphoma; 2009 Dec; 50(12):2017-29. PubMed ID: 19672773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
    Nguyen TK; Rahmani M; Harada H; Dent P; Grant S
    Blood; 2007 May; 109(9):4006-15. PubMed ID: 17218385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GW5074 and PP2 kinase inhibitors implicate nontraditional c-Raf and Lyn function as drivers of retinoic acid-induced maturation.
    Jensen HA; Bunaciu RP; Varner JD; Yen A
    Cell Signal; 2015 Aug; 27(8):1666-75. PubMed ID: 25817574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagy contributes to dasatinib-induced myeloid differentiation of human acute myeloid leukemia cells.
    Xie N; Zhong L; Liu L; Fang Y; Qi X; Cao J; Yang B; He Q; Ying M
    Biochem Pharmacol; 2014 May; 89(1):74-85. PubMed ID: 24607273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.
    Lin YC; Wu MH; Wei TT; Chuang SH; Chen KF; Cheng AL; Chen CC
    Neoplasia; 2012 Jun; 14(6):463-75. PubMed ID: 22787428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
    Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
    Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.